This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Melody Transcatheter Pulmonary Valve Study: Post Approval Study of the Original IDE Cohort (Melody IDE)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Medtronic Cardiovascular Identifier:
First received: August 21, 2008
Last updated: October 31, 2016
Last verified: October 2016
The primary objective is to confirm the long-term functionality of implantation of the Medtronic Melody TPV at 5 years is no worse than the historical control established through literature review. The secondary objectives are to assess safety, procedural success, and clinical utility of transcatheter implantation of the Melody TPV.

Condition Intervention
Congenital Heart Defects Dysfunctional Right Ventricular Outflow Tract Conduits Device: Transcatheter Pulmonary Valve replacement

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Implantation of the Medtronic Melody Transcatheter Pulmonary Valve in Patients With Dysfunctional RVOT Conduits: A Feasibility Study

Resource links provided by NLM:

Further study details as provided by Medtronic Cardiovascular:

Primary Outcome Measures:
  • Long-Term Functionality of Melody [ Time Frame: Five years ]

Secondary Outcome Measures:
  • Percent of Subjects with Procedural Success [ Time Frame: 10 years ]
  • Procedural Adverse Events [ Time Frame: 10 years ]
  • Serious Device-related Adverse Events [ Time Frame: 10 years ]
  • Stent fracture [ Time Frame: 10 years ]
  • Catheter Re-intervention on TPV [ Time Frame: 10 years ]
  • Surgical Replacement of the RVOT Conduit [ Time Frame: 10 years ]
  • Death (all-cause, procedural and device-related) [ Time Frame: 10 years ]
  • Functional Assessment (NYHA Classification) [ Time Frame: 10 years ]

Enrollment: 150
Study Start Date: January 2007
Estimated Study Completion Date: January 2020
Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Melody TPV Implant
Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.
Device: Transcatheter Pulmonary Valve replacement
Transcatheter valve implantation into a RVOTconduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
Other Name: Melody Transcatheter Pulmonary Valve


Ages Eligible for Study:   5 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age greater than or equal to 5 years of age
  • Weight greater than or equal to 30 kilograms
  • Existence of a full (circumferential) RVOT conduit that was equal to or greater than 16mm in diameter when originally implanted, or a stented bioprosthesis with a rigid circumferential sewing ring in the RVOT that has an internal diameter greater than or equal to 18mm and less than or equal to 22mm when originally implanted.
  • Any of the following by transthoracic echocardiography:
  • Patient in NYHA Classification II, III, or IV:
  • Moderate (3+) or severe (4+) pulmonary regurgitation
  • Mean RVOT gradient greater than or equal to 35mmHg
  • Patients in NYHA Classification I:
  • Severe (4+) pulmonary regurgitation with RV dilatation or dysfunction
  • Mean RVOT gradient greater or equal to 40mmHg

Exclusion Criteria:

  • Active endocarditis
  • Major or progressive non-cardiac disease (liver failure, renal failure, cancer)that has a life expectancy of less than one year
  • Patient or guardian unwilling or unable to provide written informed consent or comply with follow-up requirements
  • Obstruction of the central veins (including the superior and inferior vena cava, bilateral iliac veins) such that the delivery system cannot be advanced to the heart via transvenous approach from either femoral vein or internal jugular vein
  • Positive urine or serum pregnancy test 24 hours prior to procedure in female patients of child bearing potential
  • Known intravenous drug abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00740870

United States, Florida
Miami Children's Hospital
Miami, Florida, United States, 33155
United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
United States, New York
Children's Hospital of NY-Presbyterian
New York, New York, United States, 10032-3784
United States, Ohio
Nationwide Children's Hospital
Columbus, Ohio, United States, 43205
United States, Washington
Seattle Children's and Regional Hospital
Seattle, Washington, United States, 98105
Sponsors and Collaborators
Medtronic Cardiovascular
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Medtronic Cardiovascular Identifier: NCT00740870     History of Changes
Other Study ID Numbers: G050186
Study First Received: August 21, 2008
Last Updated: October 31, 2016

Keywords provided by Medtronic Cardiovascular:
Tetralogy of Fallot
Right Ventricular Outflow Tract

Additional relevant MeSH terms:
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities processed this record on June 23, 2017